Dayra Therapeutics has secured over $70 million, including $50 million from Biogen, to develop oral macrocyclic peptide drugs. Founded through Versant’s Frontier Discovery Engine, Dayra is led by Acting CEO Rami Hannoush, PhD, and CSO Roger Palframan, PhD. Biogen will help advance and potentially commercialise immunology candidates.